182 related articles for article (PubMed ID: 8590897)
1. In vitro and in vivo production of interleukin-6 induced by muramyl peptides and lipopolysaccharide in normal dogs.
Shi F; Kurzman ID; MacEwen EG
Cancer Biother; 1995; 10(4):317-25. PubMed ID: 8590897
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo canine mononuclear cell production of tumor necrosis factor induced by muramyl peptides and lipopolysaccharide.
Kurzman ID; Shi F; MacEwen EG
Vet Immunol Immunopathol; 1993 Sep; 38(1-2):45-56. PubMed ID: 8256437
[TBL] [Abstract][Full Text] [Related]
3. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro.
Maeda M; Knowles RD; Kleinerman ES
Cancer Commun; 1991; 3(10-11):313-21. PubMed ID: 1722107
[TBL] [Abstract][Full Text] [Related]
4. Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes.
Asano T; McWatters A; An T; Matsushima K; Kleinerman ES
J Pharmacol Exp Ther; 1994 Feb; 268(2):1032-9. PubMed ID: 8113959
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo effect of doxorubicin combined with liposome-encapsulated muramyl tripeptide on canine monocyte activation.
Shi F; MacEwen EG; Kurzman ID
Cancer Res; 1993 Sep; 53(17):3986-91. PubMed ID: 8358727
[TBL] [Abstract][Full Text] [Related]
6. Lack of production of interleukin 1 by human blood monocytes activated to the antitumor state by liposome-encapsulated muramyl tripeptide.
Tandon P; Utsugi T; Sone S
Cancer Res; 1986 Oct; 46(10):5039-44. PubMed ID: 3489519
[TBL] [Abstract][Full Text] [Related]
7. Induction of serum tumor necrosis factor-alpha and interleukin-6 activity by liposome-encapsulated muramyl tripeptide-phosphatidylethanolamine (L-MTP-PE) in normal cats.
Fox LE; King RR; Shi F; Kurzman ID; MacEwen EG; Kubilis PS
Cancer Biother; 1994; 9(4):329-40. PubMed ID: 7719380
[TBL] [Abstract][Full Text] [Related]
8. Comparative interaction of free and liposome-encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes.
Fogler WE; Fidler IJ
Int J Immunopharmacol; 1987; 9(2):141-50. PubMed ID: 3583507
[TBL] [Abstract][Full Text] [Related]
9. Anti-(tumor necrosis factor) alters the response of human monocytes to liposomal muramyl tripeptide.
Maeda M; Asano T; Kleinerman ES
Cancer Immunol Immunother; 1993 Aug; 37(3):203-8. PubMed ID: 8334682
[TBL] [Abstract][Full Text] [Related]
10. Muramyl peptides augment the in vitro and in vivo cytostatic activity of canine plastic-adherent mononuclear cells against canine osteosarcoma cells.
Smith BW; Kurzman ID; Schultz KT; Czuprynski CJ; MacEwen EG
Cancer Biother; 1993; 8(2):137-44. PubMed ID: 7804354
[TBL] [Abstract][Full Text] [Related]
11. Stereo-isomer specific induction of renal cell apoptosis by synthetic muramyl dipeptide (N-acetylmuramyl-L-alanyl-D-isoglutamine).
Langford MP; Chen D; Welbourne TC; Redens TB; Ganley JP
Mol Cell Biochem; 2002 Jul; 236(1-2):63-73. PubMed ID: 12190122
[TBL] [Abstract][Full Text] [Related]
12. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy.
Asano T; Kleinerman ES
J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):286-92. PubMed ID: 8280710
[TBL] [Abstract][Full Text] [Related]
13. Functional characteristics of the rat liver macrophage population after a single intravenous injection of liposome-encapsulated muramyl peptides.
Hoedemakers RM; Vossebeld PJ; Daemen T; Scherphof GL
J Immunother Emphasis Tumor Immunol; 1993 May; 13(4):252-60. PubMed ID: 8334109
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation.
Kleinerman ES; Meyers PA; Raymond AK; Gano JB; Jia SF; Jaffe N
J Immunother Emphasis Tumor Immunol; 1995 Apr; 17(3):181-93. PubMed ID: 7613644
[TBL] [Abstract][Full Text] [Related]
15. Modulation of lipopolysaccharide-induced cytokine gene expression in mouse bone marrow-derived macrophages by muramyl dipeptide.
Le Contel C; Temime N; Charron DJ; Parant MA
J Immunol; 1993 May; 150(10):4541-9. PubMed ID: 8482846
[TBL] [Abstract][Full Text] [Related]
16. Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanoma.
Liebes L; Walsh CM; Chachoua A; Oratz R; Richards D; Hochster H; Peace D; Marino D; Alba S; Le Sher D
J Natl Cancer Inst; 1992 May; 84(9):694-9. PubMed ID: 1569602
[TBL] [Abstract][Full Text] [Related]
17. Liposome-encapsulated muramyl tripeptide up-regulates monocyte chemotactic and activating factor gene expression in human monocytes at the transcriptional and post-transcriptional levels.
Asano T; Matsushima K; Kleinerman ES
Cancer Immunol Immunother; 1994 Jan; 38(1):16-22. PubMed ID: 8299114
[TBL] [Abstract][Full Text] [Related]
18. Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation?
Fujimaki W; Griffin JR; Kleinerman ES
Cancer Immunol Immunother; 1993; 36(1):45-51. PubMed ID: 8422667
[TBL] [Abstract][Full Text] [Related]
19. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE): a randomized clinical trial in dogs with mammary carcinoma.
Teske E; Rutteman GR; vd Ingh TS; van Noort R; Misdorp W
Anticancer Res; 1998; 18(2A):1015-9. PubMed ID: 9615757
[TBL] [Abstract][Full Text] [Related]
20. Effect of liposome-muramyl tripeptide combined with recombinant canine granulocyte colony-stimulating factor on canine monocyte activity.
Kurzman ID; Cheng H; MacEwen EG
Cancer Biother; 1994; 9(2):113-21. PubMed ID: 7529085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
